The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Results of the L-MIND trial in R/R DLBCL

Jun 24, 2019

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to our Chair, Gilles Salles, from South Lyon University Hospital Complex, Lyon, FR, about the results of the L-MIND trial in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Gilles Salles discusses how the L-MIND trial assesses the efficacy of the combination of an enhanced CD19 antibody and lenalidomide for patients with R/R DLBCL. He mentioned how the duration of the response was now close to 22 months, indicating a significant benefit for patients who are often difficult to treat.

Results of the L-MIND trial in R/R DLBCL